Affiliation:
1. Department of Pharmacology , L. M. College of Pharmacy, Gujarat Technological University , Ahmedabad , Gujarat , India
Abstract
Abstract
Objectives
Currently, there are several animal models for vasculitis. Ovalbumin and lipopolysaccharide (OVA, LPS) are well established for causing inflammation and used as an adjunct in the vasculitis induction. However, to date, none has established the effect of OVA and LPS in disease induction. Therefore, in the present study, an attempt has been made to develop a new animal model for vasculitis using OVA/LPS in rats.
Methods
A total of 42 Wistar rats were divided randomly into seven groups (n=6/group), normal control, and three different doses (0.5, 1, and 5 mg/kg) of OVA and LPS treated groups. Half of the rats in each group received only intraperitoneal sensitization, while the remaining half rats were additionally subjected to a one-week intranasal challenge.
Results
Results showed that both OVA/LPS in their respective groups have significantly increased circulating inflammatory cells, C-reactive protein (CRP), Inflammatory cytokines (IL-1β, IL-6, TNF-α), Kidney damage markers (BUN, Creatinine), and liver function enzymes (AST, ALT) in a dose-dependent manner.
Conclusions
OVA/LPS induced vascular inflammation in a dose-dependent manner. However, the higher (5 mg/kg) dose of ovalbumin and lipopolysaccharide has contributed to severe vascular inflammation through increasing inflammatory cytokines. These findings suggest that OVA/LPS may contribute as a possible model for vasculitis in rats.
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference28 articles.
1. Sharma, P, Sharma, S, Baltaro, R, Hurley, J. Systemic vasculitis. Am Fam Physician 2011;83:556–65.
2. Sneller, MC, Fauci, AS. Pathogenesis of vasculitis syndromes. Med Clin N Am 1997;81:221–42. https://doi.org/10.1016/s0025-7125(05)70512-5.
3. Guillevin, L, Dörner, T. Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Ther 2007;9(2 Suppl):S9. https://doi.org/10.1186/ar2193.
4. Wilde, B, Van Paassen, P, Witzke, O, Tervaert, JWC. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:599–612. https://doi.org/10.1038/ki.2010.472.
5. Ballanti, E, Chimenti, MS, Perricone, R. Small-medium vessel vasculitides: is the complement System a potential forgotten target? Isr Med Assoc J 2015;17:85–92.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献